Equities

Alaunos Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TCRT:NAQ

Alaunos Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.64
  • Today's Change-0.08 / -2.94%
  • Shares traded7.27k
  • 1 Year change+58.85%
  • Beta-1.2554
Data delayed at least 15 minutes, as of Feb 11 2026 20:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.

  • Revenue in USD (TTM)6.00k
  • Net income in USD-4.03m
  • Incorporated2005
  • Employees1.00
  • Location
    Alaunos Therapeutics Inc501 E Las Olas Blvd, Suite 300FORT LAUDERDALE 33301United StatesUSA
  • Phone+1 (617) 259-1970
  • Fax+1 (617) 241-2855
  • Websitehttps://alaunos.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CTT Pharmaceutical Holdings Inc0.00-1.67m5.19m0.00--2.60-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Processa Pharmaceuticals Inc0.00-12.93m5.28m10.00--0.8446-----35.00-35.000.002.760.00----0.00-206.50-104.23-270.68-112.35------------0.00-------6.55------
MetaVia Inc0.00-16.22m5.45m9.00--0.5911-----13.88-13.880.002.880.00----0.00-87.87-99.54-167.49-140.07------------0.00-------121.27---48.18--
BioRestorative Therapies Inc383.40k-12.67m5.67m11.00--2.32--14.79-1.48-1.480.04470.27660.0379--4.3034,854.55-125.35-149.02-207.73-188.7193.34---3,304.77-11,837.37----0.00--175.0325.2713.81--24.41--
Bullfrog AI Holdings Inc116.67k-6.76m5.91m9.00--2.78--50.66-0.6936-0.69360.01190.18660.0319----12,963.33-184.34---233.50--18.76---5,770.66------0.0278---100.00---31.42------
Calidi Biotherapeutics Inc0.00-25.62m5.95m28.00--0.828-----9.62-9.620.001.000.00----0.00-194.84---1,279.90-------------58.240.1544------18.49------
Alaunos Therapeutics Inc6.00k-4.03m6.07m1.00--2.14--1,011.76-2.29-2.290.00341.270.0017----6,000.00-110.67-63.80-145.65-77.93-----67,083.34-7,084.74----0.00--100.00--86.68------
enVVeno Medical Corp0.00-21.97m6.13m37.00--0.1834-----37.84-37.840.0050.980.00----0.00-53.09-52.36-56.24-55.28------------0.00------7.22---36.69--
Mustang Bio Inc0.00-2.34m6.23m6.00--0.638-----47.37-47.370.001.340.00----0.00-17.59-70.16-224.95-83.31------------0.00------69.47------
Brainstorm Cell Therapeutics Inc0.00-10.85m6.29m27.00---------1.50-1.500.00-0.69730.00----0.00-637.06-112.30---219.11--------------------32.39------
Intelligent Bio Solutions Inc3.29m-10.87m6.69m16.00--1.38--2.03-17.27-17.275.093.980.30252.745.08205,752.50-100.21-73.55-191.77-123.3043.08---331.26-476.220.7618--0.0392---1.9074.49-4.06------
Creative Medical Technology Holdings Inc6.00k-5.96m6.74m4.00--0.8907--1,124.12-2.87-2.870.00272.170.00091.10--1,500.00-93.58-83.62-98.14--60.0062.58-99,356.66-10,541.1020.70--0.00--22.22-41.85-3.91------
Aptorum Group Ltd-100.00bn-100.00bn6.83m1.00--0.2661----------3.15-----------33.06---31.53--1.65---1,009.86----0.2079---100.00---51.09------
Theriva Biologics Inc0.00-26.19m6.92m22.00--0.2967-----5.53-5.530.000.65390.00----0.00-73.83-37.94-99.55-42.02------------0.2025-------39.81------
Aptevo Therapeutics Inc0.00-27.95m6.96m37.00--0.3079-----306,220.00-306,220.000.0022.670.00----0.00-125.64-47.17-172.77-82.66-------487.43----0.00-------29.38------
Data as of Feb 11 2026. Currency figures normalised to Alaunos Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

3.28%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 30 Sep 202521.35k0.96%
Geode Capital Management LLCas of 30 Sep 202515.79k0.71%
Vanguard Fiduciary Trust Co.as of 31 Dec 202515.50k0.69%
The Vanguard Group, Inc.as of 31 Dec 202514.06k0.63%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 20251.68k0.08%
Tower Research Capital LLCas of 30 Sep 20251.63k0.07%
UBS Switzerland AG (Investment Management)as of 31 Dec 20251.24k0.06%
Osaic Wealth, Inc. (Investment Management)as of 30 Sep 20251.13k0.05%
Vanguard Global Advisers LLCas of 31 Dec 2025501.000.02%
CIBC Private Wealth Advisors, Inc.as of 30 Sep 2025300.000.01%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.